Next-generation sequencing of in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results.

PURPOSE

We evaluated the clinical role of rapid next-generation sequencing (NGS) for identifying mutations compared to traditional Sanger sequencing.

METHODS

Twenty-four paired samples from 12 patients were analyzed in this prospective study to compare the performance of NGS to the Sanger method. Both NGS and Sanger sequencing were performed in 2 different laboratories using blood samples from patients with breast cancer. We then analyzed the accuracy of NGS in terms of variant calling and determining concordance rates of mutation detection.

RESULTS

The overall concordance rate of mutation identification was 100%. Variants of unknown significance (VUS) were reported in two cases of and 3 cases of after Sanger sequencing, whereas NGS reported only 1 case of VUS, likely due to differences in reference databases used for mutation identification. The median turnaround time of Sanger sequencing was 22 days (range, 14-26 days), while the median time of NGS was only 6 days (range, 3-21 days).

CONCLUSION

NGS yielded comparably accurate results to Sanger sequencing and in a much shorter time with respect to mutation identification. The shorter turnaround time and higher accuracy of NGS may help clinicians make more timely and informed decisions regarding surgery or neoadjuvant chemotherapy in patients with breast cancer.